

Global Tumor Genomics Market: Focus on Products, Techniques, Applications, End User, Cancer Type, 14 Countries Data, Industry Insights and Competitive Landscape - Analysis and Forecast, 2019-2028

<https://marketpublishers.com/r/GAFB9F546117EN.html>

Date: May 2020

Pages: 259

Price: US\$ 5,000.00 (Single User License)

ID: GAFB9F546117EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Market Report Coverage - Tumor Genomics

Market Segmentation

By Product: Assays and Kits, and Instruments

By Technique: Next Generation Sequencing Technique (NGS), Polymerase Chain Reaction (PCR), Microarray, In-Situ Hybridization (ISH), Immunohistochemistry (ICH), Others (Mass Spectrometry and Flow Cytometry)

By Application: Diagnostics and Monitoring, Drug Discovery and Development, and Biomarker Discovery

By End User: Academics and Research Organizations, Hospitals and Ambulatory Clinics, Clinical and Diagnostic Laboratories, and Biotechnology and Pharmaceutical Company

By Cancer Type: Leukemia, Breast Cancer, Melanoma, Colon Cancer, Lung Cancer, Prostate Cancer, Head and Neck Cancer, and Others (Ovarian, Pancreatic, and Testicular)

Regional Segmentation

North America – U.S., Canada

Europe – Germany, U.K., France, Italy, Spain, Netherlands, Rest-of-Europe

Asia-Pacific – Japan, China, Australia, India, Rest-of-Asia-Pacific

Rest-of-the-World – Latin America and Middle East & Africa

Growth Drivers

Rising Government Initiatives and Projects

Increasing Incidence of Cancer

Increasing Number of Product Approvals and Launches

Ever Expanding Application Areas for Genomics

Increasing Use of Biomarkers in Cancer Profiling

Market Challenges

High Cost of Genomic Equipment

Lack of Unified Framework for Data Integration

Market Opportunities

Growing Prominence for Precision Medicine

Increasing Demand for Point-of-Care Diagnostics

Key Companies Profiled

Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, Pacific Biosciences of California, Inc., Myriad Genetics, Inc., and PerkinElmer.

Key Questions Answered:

What is tumor genomics? How the different tumor genomic techniques have evolved over the years?

What are the major market drivers, challenges, and opportunities in the global tumor genomics market?

What was the global tumor genomics market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the market size expected to be in 2028?

How is each segment of the global tumor genomics market expected to grow during the forecast period between 2020 to 2028 and what is the revenue expected to be generated by each of the segments by the end of 2028?

What are the developmental strategies implemented by the key players to sustain in the competitive market?

What is the growth potential of the tumor genomics market in each region, namely, North America, Europe, Asia-Pacific, and the Rest-of-the-World?

Which product among the two (assays and kits & instrument) are offered by key players such as Thermo Fisher Scientific, Illumina Inc., Qiagen N.V., and F. Hoffmann-La Roche Ltd.?

Which technique is leading the market in 2018 and expected to dominate the market in 2028 and why?

Which application and end user type are leading the market in 2019 and are expected to dominate the market in 2028 and why?

Which region dominated the global tumor genomics market in 2019 and what are the expected trends from each of the regions in the forecast period

2020-2028?

Market Overview

In order to meet the growing product demand and need, companies are investing in the assays, kits, and instruments used in tumor genomics. Nowadays, large number of kits and reagents are used to test the profiling of mutated genes. For instance, companies such as Thermo Fisher Scientific, Illumina, Inc., and QIAGEN N.V. have focused on the development of variety of kits for the detection of rare genetic diseases due to cost-effectiveness of the kit as compared to instrument and software, which in turn is causing widespread utilization of kits globally.

The market is also witnessing the launches of various products by receiving FDA approvals such as assay for the study of genes and molecular characterization of DNA. For instance, on, January 16, 2019, QIAGEN received approval from Japanese Pharmaceuticals and Medical Device Agency (PMDA) on theascreen EGFR RGQ PCR Kit which is used as a companion diagnostic for lung cancer patients on treatment with Dacomitinib.

Similarly, several manufacturers are also launching innovative products to expand their offerings in the market. For instance, on November 6, 2019, Thermo Fisher Scientific launched Ion Torrent Genexus System, which is a fully integrated next generation sequencing platform used for profiling of genomes.

The market is favored by multiple factors, which include rising government initiatives, increasing incidence of cancer, therefore increasing the utilization of sequencing to identify the mutant DNA segments, increasing number of product approvals and launches pertaining to genomics market. Moreover, increasing use of biomarkers in cancer profiling is also one of the key driving factors for tumor genomics market.

Government funding is also one of the major growth factors for tumor genomics market, because increasing funding by the government help the research institutes to develop sequencing systems useful for the diagnosis of genetic diseases. Increasing funding shall lead to liquidity of the genomics market and thus companies shall develop various sequencing systems to identify the mutation in the segments of DNA. All these factors are thus expected to contribute to the market growth during the forecast period.

Within the research report, the market is segmented on the basis of product type,

techniques, application, end user, cancer type, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

Major players including QIAGEN N.V., Illumina, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd. Thermo Fisher Scientific, and BGI, among others, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2019-2029, followed by Europe. This is a result of the presence of leading industry players in these regions, and a higher adoption rate of sequencing system to detect the mutation in genes and DNA segments. Moreover, growing research in the field of sequencing technologies including next-generation sequencing technologies (NGS) is one of the drivers that promote the growth of the tumor genomics market.

Contents

EXECUTIVE SUMMARY

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 RESEARCH SCOPE

2.1 Scope of the Study

2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

3.1 Global Tumor Genomics: Research Methodology

3.2 Primary Data Sources

3.3 Secondary data sources

3.4 Data Triangulation

3.5 Segmentation of the Global Tumor Genomics Market

3.6 Inclusion and Exclusion

3.7 Base Year and Forecast Year

4 GLOBAL TUMOR GENOMICS MARKET

4.1 Market Overview

4.2 Introduction to Tumor Genomics

4.3 Evolution of Tumor Genomic Techniques

4.4 Global Market Scenario and Key Technology Trends

5 MARKET DYNAMICS

5.1 Introduction

5.2 Impact Analysis

5.3 Market Drivers

5.3.1 Rising Government Initiatives and Projects

5.3.2 Increasing Incidence of Cancer

5.3.3 Increasing Number of Product Approval and Launches

5.3.4 Ever Expanding Application Areas for Genomics

5.3.5 Increasing Use of Biomarkers in Cancer Profiling

5.4 Market Restraints

5.4.1 High Cost of Genomic Equipment

5.4.2 Lack of Unified Framework for Data Integration

5.5 Market Opportunities

5.5.1 Growing Prominence for Precision Medicine

5.5.2 Increasing Demand for Point-of-Care Diagnostics

6 INDUSTRY INSIGHTS

6.1 Regulatory Requirements

6.1.1 Regulatory Framework in the U.S.

6.1.1.1 Guidelines Published in FY2018

6.1.1.2 Guidelines Published in FY2016

6.1.2 Europe

6.1.3 Japan

6.2 Patent Analysis

7 COMPETITIVE LANDSCAPE

7.1 Key Developments and Strategies

7.1.1 Partnerships and Alliances

7.1.2 New Product Launches

7.1.3 Mergers and Acquisition Activities

7.1.4 Business Expansions

7.1.5 Others

7.2 Market Share Analysis

7.2.1 Market Share Analysis (by Company)

7.3 Growth Share Analysis

7.3.1 Growth Share Matrix (by Company)

8 GLOBAL TUMOR GENOMICS MARKET (BY PRODUCT)

8.1 Assays and Kits

8.2 Instrument

9 GLOBAL TUMOR GENOMICS MARKET (BY TECHNIQUE)

9.1 Next Generation Sequencing (NGS)

9.2 Polymerase Chain Reaction (PCR)

9.3 Microarray

9.4 In-Situ Hybridization (ISH)

9.5 Immunohistochemistry (IHC)

9.6 Other Technologies (Mass Spectrometry and Flow Cytometry)

10 GLOBAL TUMOR GENOMICS MARKET (BY APPLICATION)

10.1 Diagnostics and Monitoring

10.2 Drug Discovery and Development

10.3 Biomarker Discovery

11 GLOBAL TUMOR GENOMICS MARKET (BY END USER)

11.1 Academics and Research Organizations

11.2 Hospitals and Ambulatory Clinics

11.3 Clinical and Diagnostic Laboratories

11.4 Biotechnology and Pharmaceutical Companies

12 GLOBAL TUMOR GENOMICS MARKET (BY CANCER TYPE)

12.1 Leukemia

12.2 Breast Cancer

12.3 Melanoma

12.4 Colon Cancer

12.5 Lung Cancer

12.6 Prostate Cancer

12.7 Head and Neck Cancer

12.8 Others (Ovarian, Pancreatic, and Testicular)

13 GLOBAL TUMOR GENOMICS MARKET (BY REGION)

13.1 North America

13.1.1 North America Tumor Genomics Market (by Country)

13.1.2 U.S.

13.1.3 Canada

13.2 Europe

13.2.1 Europe Tumor Genomics Market (by Country)

13.2.2 Germany

- 13.2.3 U.K.
- 13.2.4 France
- 13.2.5 Italy
- 13.2.6 Spain
- 13.2.7 Netherlands
- 13.2.8 Rest-of-Europe
- 13.3 Asia-Pacific (APAC)
 - 13.3.1 Asia-Pacific Tumor Genomics Market (by Country)
 - 13.3.2 China
 - 13.3.3 Japan
 - 13.3.4 Australia
 - 13.3.5 India
 - 13.3.6 Rest-of-Asia-Pacific
- 13.4 Rest-of-the-World
 - 13.4.1 Rest-of-the-World Tumor Genomics Market (by Country)
 - 13.4.2 Latin America
 - 13.4.3 Middle East & Africa

14 COMPANY PROFILES

- 14.1 Abbott Laboratories
 - 14.1.1 Company Overview
 - 14.1.2 Role of Abbott Laboratories in the Global Tumor Genomics Market
 - 14.1.3 Financials
 - 14.1.4 Key Insights About Financial Health of the Company
 - 14.1.5 SWOT Analysis
- 14.2 Agilent Technologies, Inc.
 - 14.2.1 Company Overview
 - 14.2.2 Role of Agilent Technologies, Inc. in the Global Tumor Genomics Market
 - 14.2.3 Financials
 - 14.2.4 Key Insights About Financial Health of the Company
 - 14.2.5 SWOT Analysis
- 14.3 Bio-Rad Laboratories, Inc.
 - 14.3.1 Company Overview
 - 14.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Tumor Genomics Market
 - 14.3.3 Financials
 - 14.3.4 Key Insights About Financial Health of the Company
 - 14.3.5 SWOT Analysis
- 14.4 Danaher Corporation

- 14.4.1 Company Overview
- 14.4.2 Role of Danaher Corporation in the Global Tumor Genomics Market
- 14.4.3 Financials
- 14.4.4 Key Insights About Financial Health of the Company
- 14.4.5 SWOT Analysis
- 14.5 F. Hoffmann-La Roche Ltd
 - 14.5.1 Company Overview
 - 14.5.2 Role of F. Hoffmann-La Roche Ltd in the Global Tumor Genomics Market
 - 14.5.3 Financials
 - 14.5.4 Key Insights About Financial Health of the Company
 - 14.5.5 SWOT Analysis
- 14.6 Fluidigm Corporation
 - 14.6.1 Company Overview
 - 14.6.2 Role of Fluidigm Corporation in the Global Tumor Genomics Market
 - 14.6.3 Financials
 - 14.6.4 Key Insights About Financial Health of the Company
 - 14.6.5 SWOT Analysis
- 14.7 General Electric Company
 - 14.7.1 Company Overview
 - 14.7.2 Role of General Electric Company in the Global Tumor Genomics Market
 - 14.7.3 Financials
 - 14.7.4 Key Insights About Financial Health of the Company
 - 14.7.5 SWOT Analysis
- 14.8 Illumina, Inc.
 - 14.8.1 Company Overview
 - 14.8.2 Role of Illumina, Inc. in the Global Tumor Genomic Market
 - 14.8.3 Financials
 - 14.8.4 Key Insights About Financial Health of the Company
 - 14.8.5 SWOT Analysis
- 14.9 Merck KGaA
 - 14.9.1 Company Overview
 - 14.9.2 Role of Merck KGaA in the Global Tumor Genomics Market
 - 14.9.3 Financials
 - 14.9.4 Key Insights About Financial Health of the Company
 - 14.9.5 SWOT Analysis
- 14.10 Myriad Genetics, Inc.
 - 14.10.1 Company Overview
 - 14.10.2 Role of Myriad Genetics, Inc. in the Global Tumor Genomics Market
 - 14.10.3 Financials

- 14.10.4 Key Insights About Financial Health of the Company
- 14.10.5 SWOT Analysis
- 14.11 Pacific Biosciences of California, Inc.
 - 14.11.1 Company Overview
 - 14.11.2 Role of Pacific Biosciences of California, Inc. in the Global Tumor Genomics Market
 - 14.11.3 Financials
 - 14.11.4 Key Insights About Financial Health of the Company
 - 14.11.5 SWOT Analysis
- 14.12 PerkinElmer
 - 14.12.1 Company Overview
 - 14.12.2 Role of PerkinElmer in the Global Tumor Genomics Market
 - 14.12.3 Financials
 - 14.12.4 Key Insights about Financial Health of the Company
 - 14.12.5 SWOT Analysis
- 14.13 QIAGEN
 - 14.13.1 Company Overview
 - 14.13.2 Role of QIAGEN in the Global Tumor Genomics Market
 - 14.13.3 Financials
 - 14.13.4 Key Insights about Financial Health of the Company
 - 14.13.5 SWOT Analysis
- 14.14 Siemens Healthineers AG
 - 14.14.1 Company Overview
 - 14.14.2 Role of Siemens Healthineers AG in the Global Tumor Genomics Market
 - 14.14.3 Financials
 - 14.14.4 Key Insights about Financial Health of the Company
 - 14.14.5 SWOT Analysis
- 14.15 Thermo Fisher Scientific Inc.
 - 14.15.1 Company Overview
 - 14.15.2 Role of Thermo Fisher Scientific Inc. in the Global Tumor Genomics Market
 - 14.15.3 Financials
 - 14.15.4 Key Insights on the Financial Health of the Company
 - 14.15.5 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 1: Key Product Launches Between May 2017-February 2020

Table 5.1: Impact Analysis of Market Drivers

Table 5.2: Impact analysis of Market Restraints

Table 5.3: Number of Product Launches (2018-2020)

Table 5.4: Number of Product Approvals (2018 and 2019)

Table 6.1: List of Major Regulatory Bodies and Associations across the World

Table 6.2: Global Tumor Genomics Market: Patent Analysis

Table 8.1: Competitive Benchmarking by Product and Technique

List Of Figures

LIST OF FIGURES

- Figure 1: Percentage of Cancer Deaths, by Type: 2007-2020
- Figure 2: Global Tumor Genomics Market Value, 2018-2028
- Figure 3: Drivers and Restraints of Global Tumor Genomics Market
- Figure 4: Share of Key Developments and Strategies, January 2017-February 2020
- Figure 5: Global Tumor Genomics Market (by Product), 2018-2028
- Figure 6: Global Tumor Genomics Market (by Technique), 2018-2028
- Figure 7: Global Tumor Genomics Market (by Application), 2018-2028
- Figure 8: Global Tumor Genomics Market (by End User), 2018-2028
- Figure 9: Global Tumor Genomics Market (by Cancer Type), 2018-2028
- Figure 10: Global Tumor Genomics Market (by Region): 2019 and 2028
- Figure 3.1: Global Tumor Genomics Market Research Methodology
- Figure 3.2: Primary Research
- Figure 3.3: Secondary Research
- Figure 3.4: Data Triangulation
- Figure 3.5: Top-Down Approach (Segment-Wise Analysis)
- Figure 3.6: Bottom-up Approach (Segment-Wise Analysis)
- Figure 3.7: Assumptions and Limitations
- Figure 3.8: Assumptions and Limitations
- Figure 3.9: Segmentation of the Global Tumor Genomics Market
- Figure 4.1: Evolution of Tumor Genomic Techniques
- Figure 4.2: Global Tumor Genomics Market Size, 2018-2028
- Figure 5.1: Incidence of Different Cancers (2014-2017)
- Figure 7.1: Competitive Landscape, January 2017-February 2020
- Figure 7.2: Share of Key Developments and Strategies, January 2017-February 2020
- Figure 7.3: Partnerships and Alliances (by Company), January 2017-February 2020
- Figure 7.4: New Product Launches (by Company), January 2017-February 2020
- Figure 7.5: Others (by Company), January 2017-February 2020
- Figure 7.6: Market Share Analysis for the Global Tumor Genomics Market, by Company (2019)
- Figure 7.7: Growth Share Matrix: Global Tumor Genomics Market (by Company), 2018-2019
- Figure 8.1: Global Tumor Genomics Market (by Product)
- Figure 8.2: Global Tumor Genomics Market (by Product), 2018-2028
- Figure 8.3: Global Tumor Genomics Market for Assays and Kits, 2018-2028
- Figure 8.4: Global Tumor Genomics Market for Instruments, 2018-2028

Figure 9.1: Global Tumor Genomics Market, by Techniques

Figure 9.2: Global Tumor Genomics Market (by Technique), 2018-2028

Figure 9.3: Global Tumor Genomics Market (Technique: Next-Generation Sequencing), 2018-2028

Figure 9.4: Global Tumor Genomics Market (Technique: Polymerase Chain Reaction), 2018-2028

Figure 9.5: Global Tumor Genomics Market (Technique: Microarray) , 2018-2028

Figure 9.6: Global Tumor Genomics Market (Technique: In-Situ Hybridization), 2018-2028

Figure 9.7: Global Tumor Genomics Market (Technique: Immunohistochemistry), 2018-2028

Figure 9.8: Global Tumor Genomics Market (Technique: Other Technologies {Mass Spectrometry and Flow Cytometry}), 2018-2028

Figure 10.1: Global Tumor Genomics Market, by Application

Figure 10.2: Global Tumor Genomics Market (by Application), 2018-2028

Figure 10.3: Global Tumor Genomics Market (Application: Diagnostics and Monitoring), 2018-2028

Figure 10.4: Global Tumor Genomics Market (Application: Drug Discovery and Development), 2018-2028

Figure 10.5: Global Tumor Genomics Market (Application: Biomarker Discovery), 2018-2028

Figure 11.1: Global Tumor Genomics Market, by End User

Figure 11.2: Global Tumor Genomics Market (by End User), 2018-2028

Figure 11.3: Global Tumor Genomics Market (End User: Academics and Research Organizations), 2018-2028

Figure 11.4: Global Tumor Genomics Market (End User: Hospitals and Ambulatory Clinics), 2018-2028

Figure 11.5: Global Tumor Genomics Market (End User: Clinical and Diagnostic Laboratories), 2018-2028

Figure 11.6: Global Tumor Genomics Market (End User: Biotechnology and Pharmaceutical Company), 2018-2028

Figure 12.1: Global Tumor Genomics Market, by Cancer Type

Figure 12.2: Global Tumor Genomics Market (by Cancer Type), 2018-2028

Figure 12.3: Global Tumor Genomics Market (Cancer Type: Leukemia), 2018-2028

Figure 12.4: Global Tumor Genomics Market (Cancer Type: Breast Cancer), 2018-2028

Figure 12.5: Global Tumor Genomics Market (Cancer Type: Melanoma), 2018-2028

Figure 12.6: Global Tumor Genomics Market (Cancer Type: Colon Cancer), 2018-2028

Figure 12.7: Global Tumor Genomics Market (Cancer Type: Lung Cancer), 2018-2028

Figure 12.8: Global Tumor Genomics Market (Cancer Type: Prostate Cancer),

2018-2028

Figure 12.9: Global Tumor Genomics Market (Cancer Type: Head and Neck Cancer), 2018-2028

Figure 12.10: Global Tumor Genomics Market (Cancer Type: Others {Ovarian, Pancreatic, and Testicular}), 2018-2028

Figure 13.1: Global Tumor Genomics Market (by Region), 2019 and 2028

Figure 13.2: North America Tumor Genomics Market, 2018-2028

Figure 13.3: North America: Market Dynamics

Figure 13.4: North America Tumor Genomics Market (by Country), 2019 and 2028

Figure 13.5: U.S. Tumor Genomics Market, 2018-2028

Figure 13.6: Canada: Tumor Genomics Market, 2018-2028

Figure 13.7: Europe: Tumor Genomics Market, 2018-2028

Figure 13.8: Europe: Market Dynamics

Figure 13.9: Europe Tumor Genomics Market (by Country), 2019 and 2028

Figure 13.10: Germany Tumor Genomics Market, 2018-2028

Figure 13.11: U.K. Tumor Genomics Market, 2018-2028

Figure 13.12: France Tumor Genomics Market, 2018-2028

Figure 13.13: Italy Tumor Genomics Market, 2018-2028

Figure 13.14: Spain Tumor Genomics Market, 2018-2028

Figure 13.15: Netherlands Tumor Genomics Market, 2018-2028

Figure 13.16: Rest-of-Europe Tumor Genomics Market, 2018-2028

Figure 13.17: Asia-Pacific: Tumor Genomics Market, 2018-2028

Figure 13.18: Asia-Pacific: Market Dynamics

Figure 13.19: Asia-Pacific Tumor Genomics Market (by Country), 2019 and 2028

Figure 13.20: China Tumor Genomics Market, 2018-2028

Figure 13.21: Japan Tumor Genomics Market, 2018-2028

Figure 13.22: Australia Tumor Genomics Market, 2018-2028

Figure 13.23: India Tumor Genomics Market, 2018-2028

Figure 13.24: Rest-of-Asia-Pacific Tumor Genomics Market, 2018-2028

Figure 13.25: Rest-of-the-World Tumor Genomics Market, 2018-2028

Figure 13.26: Rest-of-the-World (RoW): Market Dynamics

Figure 13.27: Rest-of-the-World Tumor Genomics Market (by Country), 2019 and 2028

Figure 13.28: Latin America Tumor Genomics Market, 2018-2028

Figure 13.29: Middle East & Africa Tumor Genomics Market, 2018-2028

Figure 14.1: Abbott Laboratories: Product Offerings for the Global Tumor Genomics Market

Figure 14.2: Abbott Laboratories: Overall Financials, 2017-2019

Figure 14.3: Abbott Laboratories: Revenue (by Product/Service), 2017-2019

Figure 14.4: Abbott Laboratories: Revenue (by Region), 2017-2019

Figure 14.5: Abbott Laboratories: R&D Expenditure, 2017-2019

Figure 14.6: Abbott Laboratories: SWOT Analysis

Figure 14.7: Agilent Technologies, Inc.: Product Offerings for the Global Tumor Genomics Market

Figure 14.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019

Figure 14.9: Agilent Technologies, Inc.: Revenue (by Business Model), 2017-2019

Figure 14.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019

Figure 14.11: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019

Figure 14.12: Agilent Technologies, Inc.: SWOT Analysis

Figure 14.13: Bio-Rad Laboratories, Inc.: Product Offerings for the Global Tumor Genomics Market

Figure 14.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018

Figure 14.15: Bio-Rad Laboratories, Inc.: Revenue (by Product/Service), 2016-2018

Figure 14.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018

Figure 14.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018

Figure 14.18: Bio-Rad Laboratories, Inc.: SWOT Analysis

Figure 14.19: Danaher Corporation Product Offerings for the Global Tumor Genomics Market

Figure 14.20: Danaher Corporation: Overall Financials, 2017-2019

Figure 14.21: Danaher Corporation: Revenue (by Product/Service), 2017-2019

Figure 14.22: Danaher Corporation: Revenue (by Region), 2017-2019

Figure 14.23: Danaher Corporation: R&D Expenditure, 2017-2019

Figure 14.24: Danaher Corporation: SWOT Analysis

Figure 14.25: F. Hoffman-La-Roche Ltd: Product Offerings for the Global Tumor Genomics Market

Figure 14.26: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019

Figure 14.27: F. Hoffmann-La Roche Ltd: Revenue (by Product/Service), 2017-2019

Figure 14.28: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019

Figure 14.29: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2018

Figure 14.30: F. Hoffmann-La Roche AG: SWOT Analysis

Figure 14.31: Fluidigm Corporation: Overall Product Portfolio

Figure 14.32: Fluidigm Corporation: Overall Financials, 2017-2019

Figure 14.33: Fluidigm Corporation: Revenue (by Business Segment), 2016-2018

Figure 14.34: Fluidigm Corporation: Revenue (by Region), 2016-2018

Figure 14.35: Fluidigm Corporation: R&D Expenditure, 2016-2018

Figure 14.36: Fluidigm Corporation: SWOT Analysis

Figure 14.37: General Electric Company: Product Offerings for the Global Tumor Genomics Market

Figure 14.38: General Electric Company: Overall Financials, 2017-2019

- Figure 14.39: General Electric Company: Revenue (by Business Model), 2017-2019
- Figure 14.40: General Electric Company: Revenue (by Region), 2017-2019
- Figure 14.41: General Electric Company: R&D Expenditure, 2017-2019
- Figure 14.42: General Electric Company: SWOT Analysis
- Figure 14.43: Illumina, Inc.: Product Offerings for the Global Tumor Genomics Market
- Figure 14.44: Illumina, Inc.: Overall Financials, 2016-2018
- Figure 14.45: Illumina Inc.: Revenue (by Segment), 2016-2018
- Figure 14.46: Illumina, Inc.: Revenue (by Region), 2016-2018
- Figure 14.47: Illumina, Inc.: R&D Expenditure, 2016-2018
- Figure 14.48: Illumina, Inc.: SWOT Analysis
- Figure 14.49: Merck KGaA: Product Offerings for the Global Tumor Genomics Market
- Figure 14.50: Merck KGaA: Overall Financials, 2017-2019
- Figure 14.51: Merck KGaA: Revenue (by Product/Service), 2017-2019
- Figure 14.52: Merck KGaA: Revenue (by Region), 2017-2019
- Figure 14.53: Merck KGaA: R&D Expenditure, 2017-2019
- Figure 14.54: Merck KGaA: SWOT Analysis
- Figure 14.55: Myriad Genetics, Inc.: Product Offerings for the Global Tumor Genomics Market
- Figure 14.56: Myriad Genetics, Inc.: Overall Financials, 2017-2019
- Figure 14.57: Myriad Genetics, Inc.: Revenue (by Product/Service), 2017-2019
- Figure 14.58: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
- Figure 14.59: Myriad Genetics, Inc.: SWOT Analysis
- Figure 14.60: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
- Figure 14.61: Pacific Biosciences of California, Inc.: Overall Financials, 2016-2018
- Figure 14.62: Pacific Biosciences of California, Inc.: Revenue (by Product/Service), 2016-2018
- Figure 14.63: Pacific Biosciences of California, Inc.: Revenue (by Region), 2016-2018
- Figure 14.64: Pacific Biosciences of California, Inc.: R&D Expenditure, 2016-2018
- Figure 14.65: Pacific Biosciences: SWOT Analysis
- Figure 14.66: PerkinElmer: Product Offerings for the Global Tumor Genomics Market
- Figure 14.67: Perkin Elmer: Overall Financials, 2017-2019
- Figure 14.68: PerkinElmer: Revenue (by Products & Services), 2017-2019
- Figure 14.69: PerkinElmer: Revenue (by Region), 2017-2019
- Figure 14.70: PerkinElmer: R&D Expenditure, 2017-2019
- Figure 14.71: PerkinElmer Inc.: SWOT Analysis
- Figure 14.72: QIAGEN: Product Offerings for the Global Tumor Genomics Market
- Figure 14.73: QIAGEN: Overall Financials, 2016-2018
- Figure 14.74: QIAGEN: Revenue (by Business Model), 2016-2018
- Figure 14.75: QIAGEN: Revenue (by Region), 2016-2018

Figure 14.76: QIAGEN: R&D Expenditure, 2016-2018

Figure 14.77: QIAGEN: SWOT Analysis

Figure 14.78: Siemens Healthineers AG: Product Offerings for the Global Tumor Genomics Market

Figure 14.79: Siemens Healthineers AG Overall Financials, 2017-2019

Figure 14.80: Siemens Healthineers AG: Revenue (by Product and Services), 2017-2019

Figure 14.81: Siemens Healthineers AG: Revenue (by Region), 2017-2019

Figure 14.82: Siemens Healthineers AG: R&D Expenditure, 2017-2019

Figure 14.83: Siemens Healthineers AG: SWOT Analysis

Figure 14.84: Thermo Fisher Scientific Inc.: Product Offerings for the Global Tumor Genomics Market

Figure 14.85: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019

Figure 14.86: Thermo Fisher Scientific Inc.: Net Revenue (by Business Segment), 2017-2019

Figure 14.87: Thermo Fisher Scientific Inc.: Net Revenue (by Region), 2017-2019

Figure 14.88: Thermo Fisher Scientific Inc.: R&D Expense, 2017-2019

Figure 14.89: Thermo Fisher Scientific, Inc.: SWOT Analysis

I would like to order

Product name: Global Tumor Genomics Market: Focus on Products, Techniques, Applications, End User, Cancer Type, 14 Countries Data, Industry Insights and Competitive Landscape - Analysis and Forecast, 2019-2028

Product link: <https://marketpublishers.com/r/GAFB9F546117EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAFB9F546117EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970